Journal article
Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer
C Gamell, T Gulati, B Solomon, S Haupt, Y Haupt
Molecular and Cellular Oncology | TAYLOR & FRANCIS INC | Published : 2017
Abstract
A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The work in the authors' laboratory is supported by grants from Cancer Council Victoria's Grant-in-Aid Scheme (1085154), National Health and Medical Research Council (NHMRC 1063389) and a fellowship to CG from Victoria Cancer Agency-Richard Pratt Foundation (Pratt14002).